Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib Journal Article
| Authors: | Schoenfeld, A. J.; Arbour, K. C.; Rizvi, H.; Iqbal, A. N.; Gadgeel, S. M.; Girshman, J.; Kris, M. G.; Riely, G. J.; Yu, H. A.; Hellmann, M. D. |
| Article Title: | Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib |
| Abstract: | Background: Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Now that PD-(L)1 inhibitors are routinely used as adjuvant and first-line treatments, sequential PD-(L)1 inhibition followed by osimertinib use may become more frequent and have unforeseen serious toxicity. Methods: We identified patients with EGFR-mutant NSCLC who were treated with PD-(L)1 blockade and EGFR-tyrosine kinase inhibitors (TKIs), irrespective of drug or sequence of administration (total n = 126). Patient records were reviewed to identify severe (NCI-CTCAE v5.0 grades 3-4) toxicity. Results: Fifteen percent [6 of 41, 95% confidence interval (CI) 7% to 29%] of all patients treated with sequential PD-(L)1 blockade followed later by osimertinib developed a severe irAE. Severe irAEs were most common among those who began osimertinib within 3 months of prior PD-(L)1 blockade (5 of 21, 24%, 95% CI 10% to 45%), as compared with >3-12 months (1 of 8, 13%, 95% CI 0% to 50%), >12 months (0 of 12, 0%, 95% CI 0% to 28%). By contrast, no severe irAEs were identified among patients treated with osimertinib followed by PD-(L)1 (0 of 29, 95% CI 0% to 14%) or PD-(L)1 followed by other EGFR-TKIs (afatinib or erlotinib, 0 of 27, 95% CI 0% to 15%). IrAEs occurred at a median onset of 20 days after osimertinib (range 14-167 days). All patients with irAEs required steroids and most required hospitalization. Conclusion: PD-(L)1 blockade followed by osimertinib is associated with severe irAE and is most frequent among patients who recently received PD-(L)1 blockade. No irAEs were observed when osimertinib preceded PD-(L)1 blockade or when PD-(L)1 was followed by other EGFR-TKIs. This association appears to be specific to osimertinib, as no severe irAEs occurred with administration of other EGFR-TKIs. |
| Keywords: | safety; egfr; pd-1; tki; clinical activity; osimertinib; irae |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | 5 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-05-01 |
| Start Page: | 839 |
| End Page: | 844 |
| Language: | English |
| ACCESSION: | WOS:000482490300021 |
| DOI: | 10.1093/annonc/mdz077 |
| PROVIDER: | wos |
| PUBMED: | 30847464 |
| PMCID: | PMC7360149 |
| Notes: | Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work